02 April 2019
By Dr Wendy Winnall - PCFA Research Team
Radium-223 (Xofigo) and Abiraterone (Zytiga) are two treatments used by Australian men with metastatic prostate cancer. Both are relatively effective and have acceptable side effect profiles. They work using different mechanisms of action. So it’s tempting to predict that taking both at once would be even better than taking one. However, results from a large clinical trial have now shown that this is a dangerous approach.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.